NO322254B1 - Virusliknende partikler samt fremgangsmate for fremstilling av disse, rekombinant papillomavirusantigen, vaksine,isolert og renset HPV18L1-DNA-molekeyl og anvendelse av dette. - Google Patents

Virusliknende partikler samt fremgangsmate for fremstilling av disse, rekombinant papillomavirusantigen, vaksine,isolert og renset HPV18L1-DNA-molekeyl og anvendelse av dette. Download PDF

Info

Publication number: NO322254B1
Authority: NO; Norway
Prior art keywords: hpv18; protein; dna; recombinant; dna molecule
Prior art date: 1995-03-22

Application number

NO19974322A

Other languages

English (en)

Norwegian (no)

Other versions

NO974322L (no

NO974322D0 (no

Inventor

Kathrin Ute Jansen

Hugh A George

Kathryn J Hofmann

Joseph G Joyce

Michael P Neeper

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-22

Filing date

1997-09-19

Publication date

2006-09-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27020342&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO322254(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-03-22 Priority claimed from US08/408,669 external-priority patent/US5840306A/en

1995-03-22 Priority claimed from US08/409,122 external-priority patent/US5820870A/en

1997-09-19 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1997-09-19 Publication of NO974322D0 publication Critical patent/NO974322D0/no

1997-11-24 Publication of NO974322L publication Critical patent/NO974322L/no

2006-09-04 Publication of NO322254B1 publication Critical patent/NO322254B1/no

Links

108020004414 DNA Proteins 0.000 title claims description 95
238000000034 method Methods 0.000 title claims description 34
241001631646 Papillomaviridae Species 0.000 title claims description 23
229960005486 vaccine Drugs 0.000 title claims description 15
239000002245 particle Substances 0.000 title claims description 13
102000053602 DNA Human genes 0.000 title claims description 11
238000002360 preparation method Methods 0.000 title description 12
239000000427 antigen Substances 0.000 title description 6
108091007433 antigens Proteins 0.000 title description 6
102000036639 antigens Human genes 0.000 title description 6
108090000623 proteins and genes Proteins 0.000 claims description 99
102000004169 proteins and genes Human genes 0.000 claims description 75
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 35
239000013604 expression vector Substances 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 9
238000012546 transfer Methods 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
241000341657 Human papillomavirus type 18 Species 0.000 claims description 5
102000004196 processed proteins & peptides Human genes 0.000 claims description 5
230000009466 transformation Effects 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 2
108020004511 Recombinant DNA Proteins 0.000 claims 2
238000012258 culturing Methods 0.000 claims 2
241000388169 Alphapapillomavirus 7 Species 0.000 claims 1
230000000295 complement effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
210000004027 cell Anatomy 0.000 description 61
235000018102 proteins Nutrition 0.000 description 59
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 32
239000013612 plasmid Substances 0.000 description 31
239000012634 fragment Substances 0.000 description 30
241000701806 Human papillomavirus Species 0.000 description 24
238000003752 polymerase chain reaction Methods 0.000 description 23
239000013598 vector Substances 0.000 description 21
239000002609 medium Substances 0.000 description 18
239000000523 sample Substances 0.000 description 16
101150009006 HIS3 gene Proteins 0.000 description 15
150000001413 amino acids Chemical group 0.000 description 15
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
239000000499 gel Substances 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
101150075484 MNN9 gene Proteins 0.000 description 12
101150050575 URA3 gene Proteins 0.000 description 12
239000000872 buffer Substances 0.000 description 11
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
101000641175 Human papillomavirus type 18 Major capsid protein L1 Proteins 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 9
238000010276 construction Methods 0.000 description 9
239000013615 primer Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
238000013519 translation Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
241000238631 Hexapoda Species 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
241000701447 unidentified baculovirus Species 0.000 description 8
238000001262 western blot Methods 0.000 description 8
SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 7
239000003155 DNA primer Substances 0.000 description 7
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
229940035893 uracil Drugs 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
101150101314 PRB1 gene Proteins 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
238000010367 cloning Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
239000008272 agar Substances 0.000 description 5
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
230000003321 amplification Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000004392 genitalia Anatomy 0.000 description 4
230000012010 growth Effects 0.000 description 4
229960002885 histidine Drugs 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
229960004452 methionine Drugs 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
229930024421 Adenine Natural products 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000283707 Capra Species 0.000 description 3
108090000565 Capsid Proteins Proteins 0.000 description 3
102100023321 Ceruloplasmin Human genes 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
101000803413 Human papillomavirus type 18 Minor capsid protein L2 Proteins 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
101710182846 Polyhedrin Proteins 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
210000001995 reticulocyte Anatomy 0.000 description 3
238000012216 screening Methods 0.000 description 3
241000894007 species Species 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical group NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
101150051089 A3 gene Proteins 0.000 description 2
102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
238000009010 Bradford assay Methods 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 2
102100028501 Galanin peptides Human genes 0.000 description 2
101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
101100114742 Homo sapiens CPVL gene Proteins 0.000 description 2
101100484716 Homo sapiens VHLL gene Proteins 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
241000701646 Kappapapillomavirus 2 Species 0.000 description 2
235000019766 L-Lysine Nutrition 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
229930064664 L-arginine Natural products 0.000 description 2
235000014852 L-arginine Nutrition 0.000 description 2
229930182844 L-isoleucine Natural products 0.000 description 2
101150075239 L1 gene Proteins 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000009608 Papillomavirus Infections Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
241000235648 Pichia Species 0.000 description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
244000309466 calf Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
208000019065 cervical carcinoma Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
238000007865 diluting Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
229960003136 leucine Drugs 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229940046166 oligodeoxynucleotide Drugs 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
229960005190 phenylalanine Drugs 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
235000013930 proline Nutrition 0.000 description 2
125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004044 response Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000013605 shuttle vector Substances 0.000 description 2
229910052709 silver Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
229960004799 tryptophan Drugs 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000192700 Cyanobacteria Species 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
101150094690 GAL1 gene Proteins 0.000 description 1
101150038242 GAL10 gene Proteins 0.000 description 1
102100024637 Galectin-10 Human genes 0.000 description 1
101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
101710157639 Minor capsid protein Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710136297 Protein VP2 Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010001244 Tli polymerase Proteins 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
108010045649 agarase Proteins 0.000 description 1
238000013019 agitation Methods 0.000 description 1
210000002255 anal canal Anatomy 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
208000012999 benign epithelial neoplasm Diseases 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000635 electron micrograph Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
208000024312 invasive carcinoma Diseases 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000013587 production medium Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19974322A 1995-03-22 1997-09-19 Virusliknende partikler samt fremgangsmate for fremstilling av disse, rekombinant papillomavirusantigen, vaksine,isolert og renset HPV18L1-DNA-molekeyl og anvendelse av dette. NO322254B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/408,669 US5840306A (en)	1995-03-22	1995-03-22	DNA encoding human papillomavirus type 18
US08/409,122 US5820870A (en)	1995-03-22	1995-03-22	Recombinant human papillomavirus type 18 vaccine
PCT/US1996/003649 WO1996029413A2 (en)	1995-03-22	1996-03-18	Dna encoding human papilloma virus type 18

Publications (3)

Publication Number	Publication Date
NO974322D0 NO974322D0 (no)	1997-09-19
NO974322L NO974322L (no)	1997-11-24
NO322254B1 true NO322254B1 (no)	2006-09-04

Family

ID=27020342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19974322A NO322254B1 (no)	1995-03-22	1997-09-19	Virusliknende partikler samt fremgangsmate for fremstilling av disse, rekombinant papillomavirusantigen, vaksine,isolert og renset HPV18L1-DNA-molekeyl og anvendelse av dette.

Country Status (22)

Country	Link
EP (2)	EP0817851B9 (nl)
JP (1)	JPH11502704A (nl)
KR (1)	KR100430698B1 (nl)
CN (1)	CN1100876C (nl)
AT (1)	ATE259879T1 (nl)
AU (1)	AU714533B2 (nl)
CA (1)	CA2215834C (nl)
CZ (1)	CZ291242B6 (nl)
DE (4)	DE122007000025I1 (nl)
DK (1)	DK0817851T5 (nl)
EA (1)	EA001092B1 (nl)
ES (1)	ES2213772T3 (nl)
FR (1)	FR07C0023I2 (nl)
HU (1)	HU223761B1 (nl)
IL (1)	IL117459A (nl)
NL (3)	NL300271I1 (nl)
NO (1)	NO322254B1 (nl)
NZ (1)	NZ305188A (nl)
PL (1)	PL184022B1 (nl)
PT (1)	PT817851E (nl)
SK (1)	SK284281B6 (nl)
WO (1)	WO1996029413A2 (nl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9621091D0 (en)	1996-10-09	1996-11-27	Fondation Pour Le Perfectionem	Attenuated microorganisms strains and their uses
PL336715A1 (en) *	1997-04-08	2000-07-03	Merck & Co Inc	Stabilised formulation of human papilloma virus
ZA982950B (en)	1997-04-08	1998-10-19	Merck & Co Inc	Stabilized human papillomavirus formulations
BR9913026A (pt) *	1998-08-14	2001-09-25	Merck & Co Inc	Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
AUPP765398A0 (en)	1998-12-11	1999-01-14	University Of Queensland, The	Treatment of papillomavirus infections
SI1150712T1 (sl)	1999-02-05	2009-02-28	Merck & Co Inc	Pripravek cepiva proti humanem papiloma virusu
FR2795074A1 (fr) *	1999-05-21	2000-12-22	Inst Nat Sante Rech Med	Polypeptides transporteurs d'acides amines, et en particulier du glutamate, et procedes de criblage de composes inhibiteurs ou activateurs de l'activite de transport
MY140664A (en) *	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
BRPI0811016B1 (pt)	2007-04-29	2021-09-21	Xiamen Innovax Biotech Co., Ltd.	Proteína li truncada do papiloma vírus humano tipo 16
DK2147926T3 (en) *	2007-04-29	2016-11-28	Beijing Wantai Biological Pharmacy Entpr Co Ltd	Truncated human papillomavirus type 18 L1 protein
CN101440373B (zh) *	2007-11-23	2012-09-05	上海泽润生物科技有限公司	一种截短型的18型人***状瘤病毒主要衣壳蛋白l1基因
JP2012530505A (ja) *	2009-06-25	2012-12-06	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規ヒトパピローマウイルス（ｈｐｖ）タンパク質構築物及びｈｐｖ疾患の予防におけるそれらの使用
MX348241B (es) *	2011-06-15	2017-06-01	Hong Jin Kim	Metodo para mejorar el rendimiento de produccion de la proteina l1 del virus del papiloma humano.
WO2013139744A1 (en)	2012-03-18	2013-09-26	Glaxosmithkline Biologicals S.A.	Method of vaccination against human papillomavirus
CN108276491B (zh) *	2018-02-05	2021-01-12	南京薇熙生物医药科技有限公司	一种可特异性识别hpv18 l1蛋白的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3625257A1 (de) *	1986-07-23	1988-02-04	Behringwerke Ag	Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
DE4015044A1 (de) *	1990-05-10	1991-11-14	Behringwerke Ag	Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
DE122007000018I1 (de) *	1991-07-19	2007-05-24	Univ Queensland	Polynukleotidabschnitt des HPV16-Genoms
DK0647140T3 (da) *	1992-06-25	2008-02-04	Univ Georgetown	Papillomavirusvacciner
US5437951A (en) *	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
DK1618888T3 (da) *	1993-03-09	2011-04-04	Univ Rochester	Fremstilling af humant papillomvirus-capsidprotein og viruslignende partikler

1996
- 1996-03-13 IL IL11745996A patent/IL117459A/xx active Protection Beyond IP Right Term
- 1996-03-18 DE DE1996631586 patent/DE122007000025I1/de active Pending
- 1996-03-18 EA EA199700256A patent/EA001092B1/ru not_active IP Right Cessation
- 1996-03-18 KR KR1019970706580A patent/KR100430698B1/ko not_active IP Right Cessation
- 1996-03-18 PL PL96322333A patent/PL184022B1/pl unknown
- 1996-03-18 JP JP8528535A patent/JPH11502704A/ja active Pending
- 1996-03-18 CZ CZ19972936A patent/CZ291242B6/cs not_active IP Right Cessation
- 1996-03-18 ES ES96909743T patent/ES2213772T3/es not_active Expired - Lifetime
- 1996-03-18 PT PT96909743T patent/PT817851E/pt unknown
- 1996-03-18 AT AT96909743T patent/ATE259879T1/de active
- 1996-03-18 EP EP96909743A patent/EP0817851B9/en not_active Expired - Lifetime
- 1996-03-18 CN CN96194121A patent/CN1100876C/zh not_active Expired - Lifetime
- 1996-03-18 WO PCT/US1996/003649 patent/WO1996029413A2/en active IP Right Grant
- 1996-03-18 DE DE69631586T patent/DE69631586T9/de active Active
- 1996-03-18 DK DK96909743T patent/DK0817851T5/da active
- 1996-03-18 CA CA002215834A patent/CA2215834C/en not_active Expired - Lifetime
- 1996-03-18 HU HU9801334A patent/HU223761B1/hu active IP Right Grant
- 1996-03-18 EP EP04075256A patent/EP1422294A1/en not_active Withdrawn
- 1996-03-18 SK SK1278-97A patent/SK284281B6/sk not_active IP Right Cessation
- 1996-03-18 DE DE200712000031 patent/DE122007000031I1/de active Pending
- 1996-03-18 DE DE200712000030 patent/DE122007000030I1/de active Pending
- 1996-03-18 NZ NZ305188A patent/NZ305188A/xx not_active IP Right Cessation
- 1996-03-18 AU AU53141/96A patent/AU714533B2/en not_active Expired
1997
- 1997-09-19 NO NO19974322A patent/NO322254B1/no not_active IP Right Cessation
2007
- 2007-03-14 NL NL300271C patent/NL300271I1/nl unknown
- 2007-03-14 NL NL300272C patent/NL300272I1/nl unknown
- 2007-03-14 NL NL300273C patent/NL300273I1/nl unknown
- 2007-03-20 FR FR07C0023C patent/FR07C0023I2/fr active Active

Also Published As

Publication number	Publication date
DE69631586D1 (de)	2004-03-25
IL117459A0 (en)	1996-07-23
ATE259879T1 (de)	2004-03-15
WO1996029413A2 (en)	1996-09-26
EP0817851B9 (en)	2004-08-18
AU714533B2 (en)	2000-01-06
MX9707208A (es)	1997-11-29
DE122007000025I1 (de)	2007-07-12
DE69631586T2 (de)	2005-01-27
CZ293697A3 (cs)	1998-02-18
NL300272I1 (nl)	2007-05-01
FR07C0023I2 (fr)	2012-08-03
CZ291242B6 (cs)	2003-01-15
HUP9801334A3 (en)	1999-04-28
PL322333A1 (en)	1998-01-19
WO1996029413A3 (en)	1996-11-28
NZ305188A (en)	1999-11-29
EP0817851B1 (en)	2004-02-18
CA2215834C (en)	2007-06-12
EA199700256A1 (ru)	1999-06-24
CN1100876C (zh)	2003-02-05
AU5314196A (en)	1996-10-08
HUP9801334A2 (hu)	1998-08-28
SK127897A3 (en)	1998-07-08
HU223761B1 (hu)	2005-01-28
DE69631586T9 (de)	2005-06-16
NO974322L (no)	1997-11-24
KR100430698B1 (ko)	2004-07-15
PL184022B1 (pl)	2002-08-30
DK0817851T5 (da)	2004-10-25
CA2215834A1 (en)	1996-09-26
PT817851E (pt)	2004-06-30
EA001092B1 (ru)	2000-10-30
EP0817851A2 (en)	1998-01-14
JPH11502704A (ja)	1999-03-09
DE122007000031I1 (de)	2007-07-19
ES2213772T3 (es)	2004-09-01
NL300273I1 (nl)	2007-05-01
EP1422294A1 (en)	2004-05-26
DK0817851T3 (da)	2004-08-16
SK284281B6 (sk)	2004-12-01
FR07C0023I1 (nl)	2007-04-27
DE122007000030I1 (de)	2007-07-19
NO974322D0 (no)	1997-09-19
CN1185176A (zh)	1998-06-17
NL300271I1 (nl)	2007-05-01
IL117459A (en)	2005-11-20

Legal Events

Date	Code	Title	Description
2016-03-29	MK1K	Patent expired

Publication	Publication Date	Title
US5840306A (en)	1998-11-24	DNA encoding human papillomavirus type 18
EP0817852B1 (en)	2003-08-20	Synthetic hpv6/11 hybrid l1 dna encoding human papillomavirus type 11 l1 protein
US5820870A (en)	1998-10-13	Recombinant human papillomavirus type 18 vaccine
NO322133B1 (no)	2006-08-21	Fremgangsmate for fremstilling av rensede viruslignende partikler (VLP-er) av humant papillomavirus.
US5821087A (en)	1998-10-13	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
NO322254B1 (no)	2006-09-04	Virusliknende partikler samt fremgangsmate for fremstilling av disse, rekombinant papillomavirusantigen, vaksine,isolert og renset HPV18L1-DNA-molekeyl og anvendelse av dette.
RU2161651C2 (ru)	2001-01-10	Очищенные белки вируса папилломы
WO1996015247A9 (en)	1996-08-01	Purified papillomavirus proteins
US6908615B1 (en)	2005-06-21	DNA encoding human papilloma virus type 18
CA2216827C (en)	2007-06-26	Synthetic hpv6/11 hybrid l1 dna encoding human papillomavirus type 11 l1 protein
CA2204266C (en)	2007-03-20	Purified papillomavirus proteins
MXPA97007208A (en)	1998-07-03	Desoxirribonucleico acid that codifies for human papilloma virus type 18 and use of my